Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Warner Chilcott
Age
45–80
Sex
FEMALE
Healthy volunteers
Accepted
You may be eligible if
female, 45 to 80 years of age, in good general health
postmenopausal ≥2 years, surgically or naturally
body mass index less than or equal to 32 kg/m\^2 at screening
You may not be if
no use within 3 months prior, nor use for more than 1 month at any time within 6 months of: glucocorticoids, anabolic steroids, estrogens, selective estrogen-receptor modulators (SERMs), or estrogen-related drugs, progestins, calcitonin, vitamin D supplements (\>1200 IU per day), calcitriol, calcidiol, or alfacalcidol at any dose, any bisphosphonate. fluoride (≥10 mg/day), strontium (≥50 mg/day), parathyroid hormone, investigational bone active agents.
allergic or abnormal reactions to bisphosphonates
history of cancer within 5 years, excluding squamous and basal cell carcinoma with 6 month remission
positive pregnancy test
no depot injection \>10,000 IU vitamin D in previous 9 months.
no history of GI disease that requires medication, or history of Crohn's disease, ulcerative colitis, diverticular disease, polyps, or surgery that could have changed GI structure or motility.
no history of frequent diarrhea or constipation that requires regular laxative use.
no history of alcohol or durg abuse, hyperparathyroidism, cancer previous 5 years, major surgery within 1 month prior to screening, diabetes, uncontrolled hypertension, cardiovascular, hepatic, renal or GI disease.
no active hyperthyroidism, osteomalacia, use of anticonvulsant medication, or allergic reaction to bisphosphonates
Clareo Health | Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women
